<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02535949</url>
  </required_header>
  <id_info>
    <org_study_id>TAMPITI TRIAL</org_study_id>
    <nct_id>NCT02535949</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid Mechanisms and Pharmacokinetics in Traumatic Injury</brief_title>
  <acronym>TAMPITI</acronym>
  <official_title>Tranexamic Acid Mechanisms and Pharmacokinetics in Traumatic Injury (TAMPITI TRIAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of TXA on the immune system, its&#xD;
      pharmacokinetics, as well as safety and efficacy in severely injured trauma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trauma is the leading cause of death in persons younger than 40 years. Hemorrhage is the&#xD;
      etiology in 30% of these deaths, and remains the leading cause of potentially preventable&#xD;
      mortality (66-80%) on the battlefield. Death secondary to hemorrhagic shock occurs from both&#xD;
      surgical bleeding and coagulopathy. Due to the knowledge of increased fibrinolysis promoting&#xD;
      a hypocoagulable state in severe trauma, trials have been performed to determine if&#xD;
      antifibrinolytics such as tranexamic acid (TXA) could reduce morbidity and mortality by&#xD;
      reducing death from hemorrhage. TXA is an antifibrinolytic that inhibits both plasminogen&#xD;
      activation and plasmin activity, thus preventing clot break-down rather than promoting new&#xD;
      clot formation. Despite the extensive use of TXA in many surgical populations and an&#xD;
      increasing use in severe trauma patients, TXA does not have an FDA approved indication for&#xD;
      patients with traumatic injuries. The effect of TXA on immune function has not been&#xD;
      thoroughly examined, especially in patients with severe traumatic injury. The study of the&#xD;
      effects of TXA use on endothelial activation and injury is also important due to the&#xD;
      inter-relationship between coagulation and endothelial function. Endothelial injury secondary&#xD;
      to local hypoperfusion causes acute traumatic coagulopathy with fibrinolysis. Therefore a&#xD;
      thorough and comprehensive evaluation of the effects of TXA on immune, coagulation, and&#xD;
      endothelial parameters is important to allow for a better understanding of the mechanisms of&#xD;
      action of this agent.&#xD;
&#xD;
      This is a randomized placebo controlled trial to obtain mechanism of action data,&#xD;
      pharmacokinetic information, and efficacy and safety data for the use of TXA in severely&#xD;
      injured trauma patients. Participants will be randomized into 1 of 3 treatment arms (1:1:1):&#xD;
      TXA 2 gram IV bolus, TXA 4 gram IV bolus, or placebo. The study period is from time of&#xD;
      enrollment to hospital discharge or transfer. The study intervention will occur only once&#xD;
      upon enrollment in the trial. Participants will receive study drug within two hours from&#xD;
      their initial injury. Blood samples will be drawn at multiple time points for immune&#xD;
      parameters, Pharmacodynamics, and repository samples.&#xD;
&#xD;
      Immune parameter samples will be drawn at at approximately 0, 6, 24 and 72 hours after study&#xD;
      drug/placebo administration.&#xD;
&#xD;
      Pharmacokinetic and pharmacodynamic samples will be drawn according to two schedules. Even&#xD;
      number sampling times, blood will be drawn at the approximate time points: 0, 20 min, 1 hr, 2&#xD;
      hr, 4 hr, 6 hr, 8 hr, and 12 hr. A patient sampled on odd number sampling times will have&#xD;
      samples drawn at the approximate time points: 0, 10 min, 40 min, 1.5 hr, 3 hr, 6 hr, 10 hr&#xD;
      and 24 hr.&#xD;
&#xD;
      Repository samples will be drawn at approximate time points: 0, 1, 6, 24, and 72 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">July 7, 2017</completion_date>
  <primary_completion_date type="Actual">July 4, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HLA-DR Expression on Monocytes 72 Hours After Drug or Placebo Administration in Patient Groups (0g TXA (Placebo); 2g TXA; 4g TXA).&quot;</measure>
    <time_frame>Samples Drawn through 72 hours after study initiation</time_frame>
    <description>Blood was drawn from patients at baseline (0 h, just before placebo or drug administration) and at 72 hours post placebo or drug administration. Leukocytes in these blood samples were stained with fluroescent antibodies specific for CD45, CD14, and HLA-DR, analyzed by flow cytometry, and the median fluorescen intensity (MFI) of HLA-DR signal was recorded for monocytes (CD45+CD14+). The fold change in HLA-DR expression from prior to placebo/drug administration to 72 h after placebo/drug administration (&quot;0 h : 72 h&quot;) was calculated as HLA-DR MFI72hours รท HLA-DR CD14 MFI0hours. Non-paramteric one-way ANOVA (Kruskal-Wallis test) was performed between each treatment group at the given time pont, and the p-value reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in Cytokine Profiles Between the Three Study Groups</measure>
    <time_frame>Samples Drawn through 72 hours after study initiation</time_frame>
    <description>To evaluate the effects of TXA on immune function parameters we will, in a RCT, analyze samples from 150 patients (50 in each study group), at multiple time points. Parameters are:&#xD;
a. Cytokines measured from time 0 to 72 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Leukocyte Function Parameters Between the Three Study Groups</measure>
    <time_frame>Samples Drawn through 72 hours after study initiation</time_frame>
    <description>To evaluate the effects of TXA on immune function parameters we will, in a RCT, analyze samples from 150 patients (50 in each study group), at multiple time points. Parameters are:&#xD;
a. Flow cytometric analyses on leukocytes measured from time 0 to 72 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Transfusion Volume CL</measure>
    <time_frame>24 hours</time_frame>
    <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;Total Transfusion Volume CL&quot; equals clearance (CL) affected by the covariate of Total Transfusion Volume (TxTot). This value is unitless per NONMEM reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Incidence of Thromboembolic Events (DVT, MI, PE, Stroke) in All Three Study Groups.</measure>
    <time_frame>Hospital Discharge (average 10 days)</time_frame>
    <description>The number of events per group for the incidence of thromboembolic events (DVT, MI, PE, Stroke) in all three study groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Incidence of Seizures at 24 Hours in All Three Study Groups.</measure>
    <time_frame>24 hours following TXA</time_frame>
    <description>The incidence of seizures at 24 hours in all three study groups. Number of participants with seizures are reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Incidence of All Adverse Events in All Three Study Groups</measure>
    <time_frame>Hospital Discharge (average 10 days)</time_frame>
    <description>All adverse events were totaled for each of the three study groups based on the number of incidents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Count CL</measure>
    <time_frame>24 hours</time_frame>
    <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;Platelet Count CL&quot; equals clearance (CL) affected by the covariate of Platelet Count (PLTint). This value is unitless per NONMEM reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Near Infrared Spectroscopy CL</measure>
    <time_frame>24 hours</time_frame>
    <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;Near Infrared Spectroscopy CL&quot; equals clearance (CL) affected by the covariate of Near Infrared Spectroscopy (NIRSint). This value is unitless per NONMEM reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine Count CL</measure>
    <time_frame>24 hours</time_frame>
    <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;Creatinine Count CL&quot; equals clearance (CL) affected by the covariate of Creatinine levels (SCRint). This value is unitless per NONMEM reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V2- Peripheral Volume (L/70kg)</measure>
    <time_frame>24 hours</time_frame>
    <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;V2&quot; equals Peripheral Volume in L/70kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Q- Intercompartmental Clearance (L/70kg)</measure>
    <time_frame>24 hours</time_frame>
    <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;Q&quot; equals intercompartmental clearance in L/70kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V1- Central Volume (L/70kg)</measure>
    <time_frame>24 hours</time_frame>
    <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;V1&quot; equals central volume in L/70kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL- Clearance of TXA (mL/(Min*70kg))</measure>
    <time_frame>24 hours</time_frame>
    <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;CL&quot; equals clearance of TXA in mL/(min*70kg).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Hemorrhage</condition>
  <condition>Shock</condition>
  <condition>Wounds and Injuries</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid 2 Gram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic Acid 4 Gram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
    <arm_group_label>Tranexamic Acid 2 Gram</arm_group_label>
    <arm_group_label>Tranexamic Acid 4 Gram</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with traumatic injury that are ordered to receive at least 1 blood product&#xD;
             and/or&#xD;
&#xD;
          2. Patients admitted to the Emergency Department with a traumatic injury and require&#xD;
             immediate transfer to the operating room to control the bleeding&#xD;
&#xD;
          3. Able to receive the study drug within 2 hours from estimated time of injury **Please&#xD;
             note that in circumstances where the patient initially met inclusion/exclusion&#xD;
             criteria (i.e. received blood products in the ED before a full evaluation of their&#xD;
             injuries is complete) but is later found to only have a soft tissue involved injury or&#xD;
             does not have a traumatic bleeding source), the Investigator may determine that the&#xD;
             patient should not be randomized into the trial and the patient should be considered a&#xD;
             screen failure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients known to be &lt; 18 years of age&#xD;
&#xD;
          2. Suspected Acute MI or stroke(thromboembolic and/or hemorrhagic) on admission&#xD;
&#xD;
          3. Known inherited coagulation disorders&#xD;
&#xD;
          4. Known history of thromboembolic events (DVT, PE, MI, Stroke)&#xD;
&#xD;
             โข Please note that past medical history of hemorrhagic stroke is permitted, but not&#xD;
             current admission with hemorrhagic stroke&#xD;
&#xD;
          5. Known history of seizures and/or seizure after injury/on admission related to this&#xD;
             hospitalization&#xD;
&#xD;
          6. Suspected or known pregnancy&#xD;
&#xD;
          7. Known to be lactating&#xD;
&#xD;
          8. Suspected or known prisoners&#xD;
&#xD;
          9. Futile care&#xD;
&#xD;
         10. Known current state of immunosuppression (i.e. on high dose steroids,&#xD;
             chemotherapeutics, etc.)&#xD;
&#xD;
         11. Unknown estimated time of injury 12). Patients wearing an &quot;Opt Out&quot; TAMPITI Study&#xD;
             bracelet 13). Known presence of subarachnoid hemorrhage.&#xD;
&#xD;
        14.) Isolated injuries to hands and/or feet (distal) 15.) Administration of&#xD;
        antifibrinolytics pre-hospital and/or during this ED admission prior to enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip C Spinella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 5, 2014</study_first_submitted>
  <study_first_submitted_qc>August 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <results_first_submitted>December 15, 2020</results_first_submitted>
  <results_first_submitted_qc>August 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2021</results_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 17, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02535949/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tranexamic Acid 2 Gram</title>
          <description>One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
        </group>
        <group group_id="P2">
          <title>Tranexamic Acid 4 Gram</title>
          <description>One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury&#xD;
Placebo: Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All analysis is based on the number of participants per group.</population>
      <group_list>
        <group group_id="B1">
          <title>Tranexamic Acid 2 Gram</title>
          <description>One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
        </group>
        <group group_id="B2">
          <title>Tranexamic Acid 4 Gram</title>
          <description>One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury&#xD;
Placebo: Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="149"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HLA-DR Expression on Monocytes 72 Hours After Drug or Placebo Administration in Patient Groups (0g TXA (Placebo); 2g TXA; 4g TXA).&quot;</title>
        <description>Blood was drawn from patients at baseline (0 h, just before placebo or drug administration) and at 72 hours post placebo or drug administration. Leukocytes in these blood samples were stained with fluroescent antibodies specific for CD45, CD14, and HLA-DR, analyzed by flow cytometry, and the median fluorescen intensity (MFI) of HLA-DR signal was recorded for monocytes (CD45+CD14+). The fold change in HLA-DR expression from prior to placebo/drug administration to 72 h after placebo/drug administration (&quot;0 h : 72 h&quot;) was calculated as HLA-DR MFI72hours รท HLA-DR CD14 MFI0hours. Non-paramteric one-way ANOVA (Kruskal-Wallis test) was performed between each treatment group at the given time pont, and the p-value reported.</description>
        <time_frame>Samples Drawn through 72 hours after study initiation</time_frame>
        <population>Change in HLA-DR Expression on Monocytes 72 hours after administration. Leukocytes stained with antibodies and analyzed by flow cytometry. The median fluorescen intensity of HLA-DR signal was measured for monocytes at 0 and 72 hours. Non-paramteric one-way ANOVA was performed and the p-value reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid 2 Gram</title>
            <description>One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
          <group group_id="O2">
            <title>Tranexamic Acid 4 Gram</title>
            <description>One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury&#xD;
Placebo: Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HLA-DR Expression on Monocytes 72 Hours After Drug or Placebo Administration in Patient Groups (0g TXA (Placebo); 2g TXA; 4g TXA).&quot;</title>
          <description>Blood was drawn from patients at baseline (0 h, just before placebo or drug administration) and at 72 hours post placebo or drug administration. Leukocytes in these blood samples were stained with fluroescent antibodies specific for CD45, CD14, and HLA-DR, analyzed by flow cytometry, and the median fluorescen intensity (MFI) of HLA-DR signal was recorded for monocytes (CD45+CD14+). The fold change in HLA-DR expression from prior to placebo/drug administration to 72 h after placebo/drug administration (&quot;0 h : 72 h&quot;) was calculated as HLA-DR MFI72hours รท HLA-DR CD14 MFI0hours. Non-paramteric one-way ANOVA (Kruskal-Wallis test) was performed between each treatment group at the given time pont, and the p-value reported.</description>
          <population>Change in HLA-DR Expression on Monocytes 72 hours after administration. Leukocytes stained with antibodies and analyzed by flow cytometry. The median fluorescen intensity of HLA-DR signal was measured for monocytes at 0 and 72 hours. Non-paramteric one-way ANOVA was performed and the p-value reported.</population>
          <units>fold change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.503" lower_limit="0" upper_limit="0.717"/>
                    <measurement group_id="O2" value="0.509" lower_limit="0.336" upper_limit="0.733"/>
                    <measurement group_id="O3" value="0.532" lower_limit="0.371" upper_limit="0.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences in Cytokine Profiles Between the Three Study Groups</title>
        <description>To evaluate the effects of TXA on immune function parameters we will, in a RCT, analyze samples from 150 patients (50 in each study group), at multiple time points. Parameters are:&#xD;
a. Cytokines measured from time 0 to 72 hours.</description>
        <time_frame>Samples Drawn through 72 hours after study initiation</time_frame>
        <population>Cytokine Levels at 0 and 72 hours after drug or placebo administration in patient groups. Blood was drawn, serum isolated, and frozen. Frozen sera were thawed and the listed cytokines measured uisng a multiplexed platform. Non-paramteric one-way ANOVA was performed between each treatment group, and the p- value reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid 2 Gram</title>
            <description>One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
          <group group_id="O2">
            <title>Tranexamic Acid 4 Gram</title>
            <description>One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury&#xD;
Placebo: Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Cytokine Profiles Between the Three Study Groups</title>
          <description>To evaluate the effects of TXA on immune function parameters we will, in a RCT, analyze samples from 150 patients (50 in each study group), at multiple time points. Parameters are:&#xD;
a. Cytokines measured from time 0 to 72 hours.</description>
          <population>Cytokine Levels at 0 and 72 hours after drug or placebo administration in patient groups. Blood was drawn, serum isolated, and frozen. Frozen sera were thawed and the listed cytokines measured uisng a multiplexed platform. Non-paramteric one-way ANOVA was performed between each treatment group, and the p- value reported.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ITAC hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.24" lower_limit="25.02" upper_limit="55.19"/>
                    <measurement group_id="O2" value="32.75" lower_limit="21.34" upper_limit="49.41"/>
                    <measurement group_id="O3" value="29.34" lower_limit="17.92" upper_limit="44.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITAC hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.67" lower_limit="20.76" upper_limit="41.14"/>
                    <measurement group_id="O2" value="21.69" lower_limit="13.98" upper_limit="34.58"/>
                    <measurement group_id="O3" value="21.58" lower_limit="13.8" upper_limit="33.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.79" lower_limit="46.73" upper_limit="111.19"/>
                    <measurement group_id="O2" value="67.58" lower_limit="43.91" upper_limit="125.74"/>
                    <measurement group_id="O3" value="64.69" lower_limit="39.83" upper_limit="97.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.22" lower_limit="34.07" upper_limit="107.56"/>
                    <measurement group_id="O2" value="52.88" lower_limit="38.41" upper_limit="94.83"/>
                    <measurement group_id="O3" value="61.41" lower_limit="46.09" upper_limit="96.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factalkine hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.61" lower_limit="94.4" upper_limit="328.9"/>
                    <measurement group_id="O2" value="146.23" lower_limit="103.15" upper_limit="210.32"/>
                    <measurement group_id="O3" value="141.8" lower_limit="75.83" upper_limit="223.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Factalkine hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.91" lower_limit="116.22" upper_limit="239.2"/>
                    <measurement group_id="O2" value="124.23" lower_limit="83.71" upper_limit="183.81"/>
                    <measurement group_id="O3" value="100.51" lower_limit="74.7" upper_limit="187.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNgamma hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.46" lower_limit="13.25" upper_limit="38.08"/>
                    <measurement group_id="O2" value="17.59" lower_limit="14.16" upper_limit="38.95"/>
                    <measurement group_id="O3" value="17.47" lower_limit="9.49" upper_limit="25.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFNgamma hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.89" lower_limit="12.22" upper_limit="30.44"/>
                    <measurement group_id="O2" value="14.79" lower_limit="10.89" upper_limit="29.69"/>
                    <measurement group_id="O3" value="12.98" lower_limit="9.06" upper_limit="28.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.98" lower_limit="41.93" upper_limit="235.6"/>
                    <measurement group_id="O2" value="84.39" lower_limit="46.77" upper_limit="127.73"/>
                    <measurement group_id="O3" value="105.07" lower_limit="39.75" upper_limit="250.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.76" lower_limit="14.47" upper_limit="46.13"/>
                    <measurement group_id="O2" value="42.39" lower_limit="16.48" upper_limit="64.75"/>
                    <measurement group_id="O3" value="32.38" lower_limit="19.7" upper_limit="44.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-3a hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.95" lower_limit="14.03" upper_limit="29.38"/>
                    <measurement group_id="O2" value="21.94" lower_limit="17.4" upper_limit="27.98"/>
                    <measurement group_id="O3" value="22.95" lower_limit="12.36" upper_limit="31.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-3a hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.49" lower_limit="23.43" upper_limit="132.02"/>
                    <measurement group_id="O2" value="27.61" lower_limit="23.66" upper_limit="54.31"/>
                    <measurement group_id="O3" value="31.54" lower_limit="17.89" upper_limit="50.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12p70 hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="6.81" upper_limit="17.61"/>
                    <measurement group_id="O2" value="8.64" lower_limit="6.04" upper_limit="12.65"/>
                    <measurement group_id="O3" value="8.78" lower_limit="4.89" upper_limit="13.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12p70 hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.67" lower_limit="5.86" upper_limit="14.06"/>
                    <measurement group_id="O2" value="9.45" lower_limit="5.72" upper_limit="11.9"/>
                    <measurement group_id="O3" value="7.58" lower_limit="3.78" upper_limit="17.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-13 hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="5.7" upper_limit="26.86"/>
                    <measurement group_id="O2" value="11.11" lower_limit="5.37" upper_limit="23.82"/>
                    <measurement group_id="O3" value="9.08" lower_limit="5.31" upper_limit="16.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-13 hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.11" lower_limit="5.78" upper_limit="27.37"/>
                    <measurement group_id="O2" value="10.27" lower_limit="5.24" upper_limit="20.28"/>
                    <measurement group_id="O3" value="10.28" lower_limit="4.42" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL -17A hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.51" lower_limit="11.46" upper_limit="30.35"/>
                    <measurement group_id="O2" value="15.05" lower_limit="9.9" upper_limit="24.01"/>
                    <measurement group_id="O3" value="18.73" lower_limit="11.45" upper_limit="28.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17A hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.06" lower_limit="11" upper_limit="38.72"/>
                    <measurement group_id="O2" value="16.67" lower_limit="11.07" upper_limit="26.89"/>
                    <measurement group_id="O3" value="14" lower_limit="9.35" upper_limit="29.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1beta hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" lower_limit="2.49" upper_limit="6.63"/>
                    <measurement group_id="O2" value="3.75" lower_limit="2.75" upper_limit="6.11"/>
                    <measurement group_id="O3" value="3.9" lower_limit="2.77" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1beta hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15" lower_limit="2.75" upper_limit="5.34"/>
                    <measurement group_id="O2" value="3.44" lower_limit="2.32" upper_limit="4.77"/>
                    <measurement group_id="O3" value="3.11" lower_limit="2.4" upper_limit="6.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" lower_limit="2.82" upper_limit="7.36"/>
                    <measurement group_id="O2" value="4.29" lower_limit="2.62" upper_limit="7.07"/>
                    <measurement group_id="O3" value="4.01" lower_limit="3.05" upper_limit="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2 hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" lower_limit="2.4" upper_limit="8.62"/>
                    <measurement group_id="O2" value="3.49" lower_limit="2.21" upper_limit="5.77"/>
                    <measurement group_id="O3" value="4.12" lower_limit="2.74" upper_limit="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-21 hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.28" lower_limit="3.51" upper_limit="9.74"/>
                    <measurement group_id="O2" value="6.13" lower_limit="3.64" upper_limit="9.75"/>
                    <measurement group_id="O3" value="7.02" lower_limit="3.22" upper_limit="10.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-21 hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.44" lower_limit="3.89" upper_limit="13.59"/>
                    <measurement group_id="O2" value="6.95" lower_limit="3.61" upper_limit="9.5"/>
                    <measurement group_id="O3" value="5.51" lower_limit="2.79" upper_limit="10.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4 hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.45" lower_limit="45.42" upper_limit="94.71"/>
                    <measurement group_id="O2" value="58.24" lower_limit="41.97" upper_limit="79.64"/>
                    <measurement group_id="O3" value="58.16" lower_limit="37.97" upper_limit="95.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4 hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.99" lower_limit="29.39" upper_limit="73.91"/>
                    <measurement group_id="O2" value="40.5" lower_limit="24.45" upper_limit="75.08"/>
                    <measurement group_id="O3" value="35.53" lower_limit="23.24" upper_limit="68.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-23 hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="724.45" lower_limit="445.25" upper_limit="1105.5"/>
                    <measurement group_id="O2" value="428.26" lower_limit="244.36" upper_limit="875.62"/>
                    <measurement group_id="O3" value="406.46" lower_limit="244.04" upper_limit="773.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-23 hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="589.73" lower_limit="388.72" upper_limit="893.66"/>
                    <measurement group_id="O2" value="351.47" lower_limit="258.99" upper_limit="811.79"/>
                    <measurement group_id="O3" value="399.74" lower_limit="248.94" upper_limit="971.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-5 hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="4.12" upper_limit="15.79"/>
                    <measurement group_id="O2" value="9.48" lower_limit="5.17" upper_limit="15.28"/>
                    <measurement group_id="O3" value="9.06" lower_limit="5.72" upper_limit="13.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-5 hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.68" lower_limit="6.31" upper_limit="17.87"/>
                    <measurement group_id="O2" value="8.05" lower_limit="6.12" upper_limit="15.22"/>
                    <measurement group_id="O3" value="8.32" lower_limit="6.94" upper_limit="13.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.48" lower_limit="23" upper_limit="182.07"/>
                    <measurement group_id="O2" value="39.7" lower_limit="18.27" upper_limit="97.99"/>
                    <measurement group_id="O3" value="63.56" lower_limit="28.05" upper_limit="110.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6 hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.97" lower_limit="35.27" upper_limit="156.11"/>
                    <measurement group_id="O2" value="67.95" lower_limit="32.83" upper_limit="149.24"/>
                    <measurement group_id="O3" value="41.9" lower_limit="21.71" upper_limit="70.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7 hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.53" lower_limit="12.67" upper_limit="30.56"/>
                    <measurement group_id="O2" value="15.33" lower_limit="11.47" upper_limit="24.3"/>
                    <measurement group_id="O3" value="16.52" lower_limit="10.19" upper_limit="23.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7 hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.47" lower_limit="11.19" upper_limit="27.49"/>
                    <measurement group_id="O2" value="16.24" lower_limit="11" upper_limit="22.19"/>
                    <measurement group_id="O3" value="16.8" lower_limit="10.93" upper_limit="19.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8 hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.25" lower_limit="10.43" upper_limit="31.68"/>
                    <measurement group_id="O2" value="13.59" lower_limit="9.62" upper_limit="24.65"/>
                    <measurement group_id="O3" value="13.78" lower_limit="8.03" upper_limit="26.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8 hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" lower_limit="18" upper_limit="42.11"/>
                    <measurement group_id="O2" value="23.05" lower_limit="17.14" upper_limit="38.97"/>
                    <measurement group_id="O3" value="17.64" lower_limit="13.78" upper_limit="23.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1alpha hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.57" lower_limit="22.77" upper_limit="42.48"/>
                    <measurement group_id="O2" value="30.98" lower_limit="20.36" upper_limit="42.9"/>
                    <measurement group_id="O3" value="27.85" lower_limit="21.99" upper_limit="41.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1alpha hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.57" lower_limit="20.69" upper_limit="43.98"/>
                    <measurement group_id="O2" value="27.24" lower_limit="18.05" upper_limit="39.23"/>
                    <measurement group_id="O3" value="25.47" lower_limit="17.29" upper_limit="43.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-beta hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.91" lower_limit="31.8" upper_limit="54.57"/>
                    <measurement group_id="O2" value="37.66" lower_limit="13.55" upper_limit="48.35"/>
                    <measurement group_id="O3" value="35.44" lower_limit="24.74" upper_limit="50.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-beta hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.78" lower_limit="25.72" upper_limit="45.65"/>
                    <measurement group_id="O2" value="29.02" lower_limit="23.15" upper_limit="39.4"/>
                    <measurement group_id="O3" value="28.15" lower_limit="22.23" upper_limit="36.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFa hour 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.16" lower_limit="13.34" upper_limit="23.46"/>
                    <measurement group_id="O2" value="16.4" lower_limit="13.3" upper_limit="20.5"/>
                    <measurement group_id="O3" value="16.4" lower_limit="12.3" upper_limit="21.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFa hour 72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.38" lower_limit="17.57" upper_limit="25.85"/>
                    <measurement group_id="O2" value="20.09" lower_limit="15.82" upper_limit="25.62"/>
                    <measurement group_id="O3" value="16.16" lower_limit="12.37" upper_limit="21.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences in Leukocyte Function Parameters Between the Three Study Groups</title>
        <description>To evaluate the effects of TXA on immune function parameters we will, in a RCT, analyze samples from 150 patients (50 in each study group), at multiple time points. Parameters are:&#xD;
a. Flow cytometric analyses on leukocytes measured from time 0 to 72 hours.</description>
        <time_frame>Samples Drawn through 72 hours after study initiation</time_frame>
        <population>Change in CD11b and CD16 Expression on neutrophils 72 hours after. Leukocytes stained with antibodies specific and analyzed by flow cytometry. The median fluorescen intensity of CD11b or CD16 signal was measured on neutrophils. The fold change was measured, MFI72hours/MFI0hours. Non-paramteric one-way ANOVA was performed and the p-value reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid 2 Gram</title>
            <description>One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
          <group group_id="O2">
            <title>Tranexamic Acid 4 Gram</title>
            <description>One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury&#xD;
Placebo: Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Leukocyte Function Parameters Between the Three Study Groups</title>
          <description>To evaluate the effects of TXA on immune function parameters we will, in a RCT, analyze samples from 150 patients (50 in each study group), at multiple time points. Parameters are:&#xD;
a. Flow cytometric analyses on leukocytes measured from time 0 to 72 hours.</description>
          <population>Change in CD11b and CD16 Expression on neutrophils 72 hours after. Leukocytes stained with antibodies specific and analyzed by flow cytometry. The median fluorescen intensity of CD11b or CD16 signal was measured on neutrophils. The fold change was measured, MFI72hours/MFI0hours. Non-paramteric one-way ANOVA was performed and the p-value reported.</population>
          <units>Fold Change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD 11b+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.875" lower_limit="0.667" upper_limit="1.11"/>
                    <measurement group_id="O2" value="0.967" lower_limit="0.802" upper_limit="1.207"/>
                    <measurement group_id="O3" value="0.844" lower_limit="0.713" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD 16+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.917" lower_limit="0.733" upper_limit="0.994"/>
                    <measurement group_id="O2" value="0.870" lower_limit="0.731" upper_limit="0.994"/>
                    <measurement group_id="O3" value="0.817" lower_limit="0.703" upper_limit="0.942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Transfusion Volume CL</title>
        <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;Total Transfusion Volume CL&quot; equals clearance (CL) affected by the covariate of Total Transfusion Volume (TxTot). This value is unitless per NONMEM reporting.</description>
        <time_frame>24 hours</time_frame>
        <population>Of the 99 participants analyzed, 49 received the 2 gram dose and 50 received the 4 gram dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid 2 Gram and 4 Gram</title>
            <description>One time dose IV TXA 2 Grams or 4 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Transfusion Volume CL</title>
          <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;Total Transfusion Volume CL&quot; equals clearance (CL) affected by the covariate of Total Transfusion Volume (TxTot). This value is unitless per NONMEM reporting.</description>
          <population>Of the 99 participants analyzed, 49 received the 2 gram dose and 50 received the 4 gram dose.</population>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="0.007" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine the Incidence of Thromboembolic Events (DVT, MI, PE, Stroke) in All Three Study Groups.</title>
        <description>The number of events per group for the incidence of thromboembolic events (DVT, MI, PE, Stroke) in all three study groups.</description>
        <time_frame>Hospital Discharge (average 10 days)</time_frame>
        <population>The incidence of thromboembolic events (DVT, MI, PE, Stroke) in all three study groups are given based on events per group.</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid 2 Gram</title>
            <description>One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
          <group group_id="O2">
            <title>Tranexamic Acid 4 Gram</title>
            <description>One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury&#xD;
Placebo: Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Incidence of Thromboembolic Events (DVT, MI, PE, Stroke) in All Three Study Groups.</title>
          <description>The number of events per group for the incidence of thromboembolic events (DVT, MI, PE, Stroke) in all three study groups.</description>
          <population>The incidence of thromboembolic events (DVT, MI, PE, Stroke) in all three study groups are given based on events per group.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine the Incidence of Seizures at 24 Hours in All Three Study Groups.</title>
        <description>The incidence of seizures at 24 hours in all three study groups. Number of participants with seizures are reported</description>
        <time_frame>24 hours following TXA</time_frame>
        <population>The incidence of seizures at 24 hours in all three study groups. This was done by totaling the number of participants with reported seizures.</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid 2 Gram</title>
            <description>One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
          <group group_id="O2">
            <title>Tranexamic Acid 4 Gram</title>
            <description>One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury&#xD;
Placebo: Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Incidence of Seizures at 24 Hours in All Three Study Groups.</title>
          <description>The incidence of seizures at 24 hours in all three study groups. Number of participants with seizures are reported</description>
          <population>The incidence of seizures at 24 hours in all three study groups. This was done by totaling the number of participants with reported seizures.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine the Incidence of All Adverse Events in All Three Study Groups</title>
        <description>All adverse events were totaled for each of the three study groups based on the number of incidents.</description>
        <time_frame>Hospital Discharge (average 10 days)</time_frame>
        <population>The number of incidents were totaled for the three study groups.</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid 2 Gram</title>
            <description>One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
          <group group_id="O2">
            <title>Tranexamic Acid 4 Gram</title>
            <description>One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury&#xD;
Placebo: Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Incidence of All Adverse Events in All Three Study Groups</title>
          <description>All adverse events were totaled for each of the three study groups based on the number of incidents.</description>
          <population>The number of incidents were totaled for the three study groups.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="264"/>
                    <measurement group_id="O3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Count CL</title>
        <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;Platelet Count CL&quot; equals clearance (CL) affected by the covariate of Platelet Count (PLTint). This value is unitless per NONMEM reporting.</description>
        <time_frame>24 hours</time_frame>
        <population>Of the 99 participants analyzed, 49 received the 2 gram dose and 50 received the 4 gram dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid 2 Gram and 4 Gram</title>
            <description>One time dose IV TXA 2 Grams or 4 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Count CL</title>
          <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;Platelet Count CL&quot; equals clearance (CL) affected by the covariate of Platelet Count (PLTint). This value is unitless per NONMEM reporting.</description>
          <population>Of the 99 participants analyzed, 49 received the 2 gram dose and 50 received the 4 gram dose.</population>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" lower_limit="0.28" upper_limit="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Near Infrared Spectroscopy CL</title>
        <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;Near Infrared Spectroscopy CL&quot; equals clearance (CL) affected by the covariate of Near Infrared Spectroscopy (NIRSint). This value is unitless per NONMEM reporting.</description>
        <time_frame>24 hours</time_frame>
        <population>Of the 99 participants analyzed, 49 received the 2 gram dose and 50 received the 4 gram dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid 2 Gram and 4 Gram</title>
            <description>One time dose IV TXA 2 Grams or 4 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
        </group_list>
        <measure>
          <title>Near Infrared Spectroscopy CL</title>
          <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;Near Infrared Spectroscopy CL&quot; equals clearance (CL) affected by the covariate of Near Infrared Spectroscopy (NIRSint). This value is unitless per NONMEM reporting.</description>
          <population>Of the 99 participants analyzed, 49 received the 2 gram dose and 50 received the 4 gram dose.</population>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" lower_limit="-0.38" upper_limit="-0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine Count CL</title>
        <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;Creatinine Count CL&quot; equals clearance (CL) affected by the covariate of Creatinine levels (SCRint). This value is unitless per NONMEM reporting.</description>
        <time_frame>24 hours</time_frame>
        <population>Of the 99 participants analyzed, 49 received the 2 gram dose and 50 received the 4 gram dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid 2 Gram and 4 Gram</title>
            <description>One time dose IV TXA 2 Grams or 4 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine Count CL</title>
          <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;Creatinine Count CL&quot; equals clearance (CL) affected by the covariate of Creatinine levels (SCRint). This value is unitless per NONMEM reporting.</description>
          <population>Of the 99 participants analyzed, 49 received the 2 gram dose and 50 received the 4 gram dose.</population>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.084" lower_limit="-0.13" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>V2- Peripheral Volume (L/70kg)</title>
        <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;V2&quot; equals Peripheral Volume in L/70kg.</description>
        <time_frame>24 hours</time_frame>
        <population>Of the 99 participants analyzed 49 received the 2 gram dose and 50 received the 4 gram dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid 2 Gram and 4 Gram</title>
            <description>One time dose IV TXA 2 Grams or 4 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
        </group_list>
        <measure>
          <title>V2- Peripheral Volume (L/70kg)</title>
          <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;V2&quot; equals Peripheral Volume in L/70kg.</description>
          <population>Of the 99 participants analyzed 49 received the 2 gram dose and 50 received the 4 gram dose.</population>
          <units>L/70kg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1080" lower_limit="959" upper_limit="1200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Q- Intercompartmental Clearance (L/70kg)</title>
        <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;Q&quot; equals intercompartmental clearance in L/70kg.</description>
        <time_frame>24 hours</time_frame>
        <population>Of the 99 participants analyzed, 49 received the 2 gram dose and 50 received the 4 gram dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid 2 Gram and 4 Gram</title>
            <description>One time dose IV TXA 2 Grams or 4 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
        </group_list>
        <measure>
          <title>Q- Intercompartmental Clearance (L/70kg)</title>
          <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;Q&quot; equals intercompartmental clearance in L/70kg.</description>
          <population>Of the 99 participants analyzed, 49 received the 2 gram dose and 50 received the 4 gram dose.</population>
          <units>L/70kg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174" lower_limit="128" upper_limit="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>V1- Central Volume (L/70kg)</title>
        <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;V1&quot; equals central volume in L/70kg.</description>
        <time_frame>24 hours</time_frame>
        <population>Of the 99 participants analyzed, 49 received the 2 gram dose and 50 received the 4 gram dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid 2 Gram and 4 Gram</title>
            <description>One time dose IV TXA 2 Grams or 4 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
        </group_list>
        <measure>
          <title>V1- Central Volume (L/70kg)</title>
          <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;V1&quot; equals central volume in L/70kg.</description>
          <population>Of the 99 participants analyzed, 49 received the 2 gram dose and 50 received the 4 gram dose.</population>
          <units>L/70kg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1160" lower_limit="968" upper_limit="1350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL- Clearance of TXA (mL/(Min*70kg))</title>
        <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;CL&quot; equals clearance of TXA in mL/(min*70kg).</description>
        <time_frame>24 hours</time_frame>
        <population>Of the 99 participants analyzed, 49 received the 2 gram dose and 50 received the 4 gram dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Tranexamic Acid 2 Gram and 4 Gram</title>
            <description>One time dose IV TXA 2 Grams or 4 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
          </group>
        </group_list>
        <measure>
          <title>CL- Clearance of TXA (mL/(Min*70kg))</title>
          <description>Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).&#xD;
Equations from optimal model:&#xD;
CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)&#xD;
&quot;CL&quot; equals clearance of TXA in mL/(min*70kg).</description>
          <population>Of the 99 participants analyzed, 49 received the 2 gram dose and 50 received the 4 gram dose.</population>
          <units>mL/(min*70kg)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" lower_limit="100" upper_limit="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tranexamic Acid 2 Gram</title>
          <description>One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
        </group>
        <group group_id="E2">
          <title>Tranexamic Acid 4 Gram</title>
          <description>One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury&#xD;
Tranexamic Acid: Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury&#xD;
Placebo: Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>acute blood loss/anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Anastomatic Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Arterial Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute desaturation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hyperphosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>SVT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Philip Spinella</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-286-0858</phone>
      <email>pspinella@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

